WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...

Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...

Please provide your email address to receive an email when new articles are posted on . T-cell lymphoma following CAR-T is rare. Tissue collection imperative to continue research into CAR-T toxicities ...